Labiotech.eu

News and Trends 15 Sep 2015

Will bacteriophages solve the antibiotic resistance problem in the EU?

French Pherecydes Pharma has launched the first EU clinical bacteriophage phase I/II trial to fight hospital acquired infections (HAIs) in military hospitals and burn units. In collaboration with two other French biotechs, the Phagoburn project aims to combat the stigma against human bacteriophage therapies in the EU and US in order to battle the oncoming […]

September 15, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 15 Sep 2015

Louvain-la-Neuve: A Belgian temple for success in cell therapy

Artificial three-dimensional tissues to regenerate bones and soft tissues: Novadip Biosciences’ dream is a step closer to reality after successfully closing a €28M Series A round. The spin-off of Université Catholique de Louvain coexists with Celyad and Promethera in a biotech cluster where cell therapy is the key protagonist. The financing round, led by New […]

September 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Sep 2015

The 9 EU-based Billion-Euro Biotechs you Should (really) Know

Update 22/10/2015: I added Galapagos from Belgium and Basilea from Switzerland, they deserved it … Talking about billon-dollar companies in the US is such a hype. Even the Wall street journal has its own start-up club (which btw is stunning). By looking at it, I wondered which European Biotechs were worth over €1Bn in Europe. […]

September 15, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 14 Sep 2015

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

TxCell, from Nice (Fr), has been granted EU and US Orphan Drug Designation for its T-cell based therapy for autoimmune uveitis – an eye inflammatory disease responsible of 10-15% legal blindness in developed countries. TxCell is a spin-off from France’s National Institute for Health and Medical Research (Inserm), with a pipeline including a phase II […]

September 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

Market holds their breath with whispers of €2.2BN hyperkalemia offer from Actelion

ZS Pharma shares shot up by 30% in value this week due to Swiss big-pharma Actelion admitting it might be interested in buying out the biotech for €2.2BN. This comes as ZS Pharma’s hyperkalemia candidate is set to receive FDA approval for May 2016, although this acquisition rumour could be premature given competitor Relypsa is […]

September 14, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

64 million infected: A brief overview of ReViral and its RSV vaccine competition

Respiratory Syncytial Virus (RSV) affects millions annually, therefore attracting many large biotechs to research a vaccine. ReViral (London, UK) has secured €18.5M series A investment into its pre-clinical pipeline. VC investors Edmond de Rothschild, OrbiMed and Brace Pharma Capital back this award winning antiviral program, despite an array of competitors. ReViral have got the go […]

September 14, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

High-Throughput screening of drug candidates made easier by FRETinFLOW

A multidisciplinary team from France has come up with a robust approach to detect molecular interactions in a reliable way using flow cytometry. This technology could lead to the discovery of new drugs via High-Throughput screening. Flow cytometry is a laser-based, biophysical technology employed by scientists all over the world to count and sort cells. It does this by […]

September 14, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 13 Sep 2015

What happened this week? An award for Kymab, disappointment for Crowdfunding and some Wasps to save us!

Monday: A report said that the total value of crowdfunded Biotech projects from within the EU since 2010 is €23M. Tuesday: Researchers from University of Leeds unraveled the mechanism of cancer-targeting effects of Wasp venom. Wednesday: Kymab has been listed in the Sunday Times Tech Track ‘One’s to Watch’ 2015 just this month! Thursday: CureVac just announced the opening of its subsidiary […]

September 13, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 12 Sep 2015

London’s Stock Market is on Fire: Two New Biotech Companies are Going Public

After the invasion of the London stock exchange by US-based companies PureTech (€147M raised) and Verseon (€92M raised) last June, it’s now the turn of two EU companies to go public in the British capital. Shield Therapeutics wants to grab a massive £110 million, while Faron Pharmaceuticals had not disclose its intention yet. Faron, based in Turku (Finland), […]

September 12, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 12 Sep 2015

Top 5 things from outside the EU you need to know this week (Theranos, Google…again, Biogen)

Oh hey there…another Top 5 topics you need to know from outside Europe this week. Hope you enjoy and if you have time, give us some feedback! FOUNDER OF THERANOS: MODERN DIAGNOSIS OF DISEASE IS TOO LATE “If you look up the word ‘diagnose’ in the dictionary, it’ll say ‘to determine the presence of disease from […]

September 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Sep 2015

Breast-milk therapy for Microbiome disease makes BioGaia smile

BioGaia is a leading microbiome biotech from Stockholm (Sweden) who use the beneficial bacterium Lactobacillus reuteri to produce probiotic consumables. The biotech is currently investing millions in another Stockholm biotech, Infant Bacterial Therapeutics (IBT). IBT is developing a therapy for Necrotising enterocolitis (NEC) derived from L.reuteri, which is found in human breast-milk. BioGaia is a […]

September 11, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 11 Sep 2015

Cambridge Love Triangle: Leading Biotechs Abcam and Horizon finally collaborate together

This is the story of how Abcam and Horizon fell in collaborative-biotech-love and finally came together to partner up on antibody research. Whilst doing his post-doc at University of Cambridge, Jonathan Milner had an idea to improve how antibodies could be produced for researchers around the World. Thus, he founded the company Abcam in 1998. Over […]

September 11, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Will bacteriophages solve the antibiotic resistance problem in the EU?

Louvain-la-Neuve: A Belgian temple for success in cell therapy

The 9 EU-based Billion-Euro Biotechs you Should (really) Know

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

Market holds their breath with whispers of €2.2BN hyperkalemia offer from Actelion

64 million infected: A brief overview of ReViral and its RSV vaccine competition

High-Throughput screening of drug candidates made easier by FRETinFLOW

What happened this week? An award for Kymab, disappointment for Crowdfunding and some Wasps to save us!

London’s Stock Market is on Fire: Two New Biotech Companies are Going Public

Top 5 things from outside the EU you need to know this week (Theranos, Google…again, Biogen)

Breast-milk therapy for Microbiome disease makes BioGaia smile

Cambridge Love Triangle: Leading Biotechs Abcam and Horizon finally collaborate together

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!